Pathways and biological functions associated with EZH2 target genes in GC B cells
| . | No. of genes (expected) . | Overrepresentation P . | Example genes . |
|---|---|---|---|
| GO biological processes | |||
| Skeletal system development | 33 (10) | < 10−9 | TWIST1 |
| Synaptic transmission | 34 (15) | < 10−5 | CHRNB1 |
| Central nervous system development | 25 (10) | < 10−5 | SHH, PAX6 |
| Regulation of cell differentiation | 21 (8) | < 10−4 | HOXA7, NOTCH2 |
| Positive regulation of cell proliferation | 37 (16) | < 10−5 | EGFR,TGFBR1,VEGFA |
| Positive regulation of ossification | 8 (1) | < 10−4 | TGFB2, BMP7 |
| Enzyme-linked receptor protein signaling pathway | 44 (17) | < 10−8 | FLT3, TGFBR1, PDGFRA |
| GO molecular function | |||
| RNA polymerase II transcription factor activity | 37 (18) | < 10−4 | MYOD1, NEUROD1 |
| Sequence-specific DNA binding | 22 (7) | < 10−5 | TBX1, TBX3 |
| Voltage-gated cation channel activity | 17 (7) | < .001 | CACNG4 |
| Potassium channel activity | 14 (5) | < .001 | KCNK1 |
| Vascular endothelial growth factor receptor activity | 6 (1) | < 10−5 | FLT1, FLT3 |
| Transmembrane receptor protein kinase activity | 20 (5) | < 10−6 | ERRB4,EGFR,TGFBR1, FLT1 |
| KEGG pathway | |||
| Calcium signaling pathway | 40 (21) | < 10−4 | CACNA1E |
| Neuroactive ligand-receptor interaction | 65 (36) | < 10−6 | GABRA2 |
| Wnt signaling pathway | 37 (17) | < 10−5 | FZD1, WNT1 |
| TGF-β signaling pathway | 22 (10) | < .001 | TGFBR1, SMAD3 |
| . | No. of genes (expected) . | Overrepresentation P . | Example genes . |
|---|---|---|---|
| GO biological processes | |||
| Skeletal system development | 33 (10) | < 10−9 | TWIST1 |
| Synaptic transmission | 34 (15) | < 10−5 | CHRNB1 |
| Central nervous system development | 25 (10) | < 10−5 | SHH, PAX6 |
| Regulation of cell differentiation | 21 (8) | < 10−4 | HOXA7, NOTCH2 |
| Positive regulation of cell proliferation | 37 (16) | < 10−5 | EGFR,TGFBR1,VEGFA |
| Positive regulation of ossification | 8 (1) | < 10−4 | TGFB2, BMP7 |
| Enzyme-linked receptor protein signaling pathway | 44 (17) | < 10−8 | FLT3, TGFBR1, PDGFRA |
| GO molecular function | |||
| RNA polymerase II transcription factor activity | 37 (18) | < 10−4 | MYOD1, NEUROD1 |
| Sequence-specific DNA binding | 22 (7) | < 10−5 | TBX1, TBX3 |
| Voltage-gated cation channel activity | 17 (7) | < .001 | CACNG4 |
| Potassium channel activity | 14 (5) | < .001 | KCNK1 |
| Vascular endothelial growth factor receptor activity | 6 (1) | < 10−5 | FLT1, FLT3 |
| Transmembrane receptor protein kinase activity | 20 (5) | < 10−6 | ERRB4,EGFR,TGFBR1, FLT1 |
| KEGG pathway | |||
| Calcium signaling pathway | 40 (21) | < 10−4 | CACNA1E |
| Neuroactive ligand-receptor interaction | 65 (36) | < 10−6 | GABRA2 |
| Wnt signaling pathway | 37 (17) | < 10−5 | FZD1, WNT1 |
| TGF-β signaling pathway | 22 (10) | < .001 | TGFBR1, SMAD3 |
Each row of data corresponds to a pathway or function enriched among EZH2 target genes in GC B cells. The first column indicates the name of the pathway or function. The second column indicates the number of genes in that pathway/function, with expected number (by chance) in parentheses. The third column shows the overrepresentation P values, calculated using the hypergeometric distribution. The fourth column shows example EZH2 target genes from the enriched categories.